

Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Thursday 29 June 2016 10:15 – 17:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:

1. Professor Gary McVeigh, Chair	Present for all notes
2. Dr Lindsay Smith, Vice Chair	Present for all notes
3. Dr Andrew Black	Present for all notes
4. Dr Matthew Bradley	Present for all notes
5. Dr Ian Campbell	Present for all notes
6. Dr Ian Davidson	Present for all notes
7. Professor Simon Dixon	Present for all notes
8. Mrs Susan Dutton	Present for all notes
9. Professor Paula Ghaneh	Present for all notes
10. Dr Susan Griffin	Present for all notes
11. Professor John Henderson	Present for all notes
12. Mr Malcolm Oswald	Present for all notes
13. Professor Oluwafemi Oyebode	Present for all notes
14. Dr Paul Miller	Present for all notes
15. Mrs Gail Coster	Present for all notes

In attendance:

Dr Tim Benepal	British Thoracic Oncology Group	Present for notes 01 to 11
Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes 01 to 12
Miriam Brazelli	ERG representative Aberdeen HTA Group	Present for notes 01 to 11
Dr Martin Forster	Clinical Expert, University College London Hospitals NHS Foundation Trust	Present for notes 01 to 11
Dr Jesme Fox	Patient Expert Roy Castle Lung Cancer Foundation	Present for notes 01 to 11
Beatrix Goulao	ERG representative Aberdeen HTA Group	Present for notes 01 to 11
Helen Knight	Associate Director, National Institute for Health and Care	Present for all notes 01 to 12

	Excellence	
Fay McCracken	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 01 to 11
Nicola McMeekin	ERG representative Aberdeen HTA Group	Present for notes 01 to 11
Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes 01 to 12
Paula O'Grady	Administrator, National Institute for Health and Care Excellence	Present for all notes 01 to 12
Nwamaka Umeweni	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 12
Olivia Wu	ERG representative Aberdeen HTA Group	Present for notes 01 to 11
Stuart Wood	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 01 to 11
Non-public observers:		
Eva Barkauskaite	Technical Analyst, Scientific Advice, National institute for Health and Care excellence	Present for all notes 01 to 12
Ann Greenwood	Senior Medical Editor, National Institute for Health and Care Excellence	Present for notes 01 to 12
Caroline Hayto	Administrator, National Institute for Health and Care Excellence	Present for notes 01 to 11
Laura Norburn	Senior Manager - Shared Decision Making, Public Involvement Programme (PIP), National Institute for Health and Care Excellence	Present for notes 01 to 11

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy and necitumumab for untreated advanced or metastatic, squamous non-small-cell lung cancer
2. The Chair informed the Committee of the non-public observers at this meeting: Eva Barkauskaite, Ann Greenwood, Caroline Hayto and Laura Norburn.
3. Apologies were received from Dr Aomesh Bhatt, Dr David Bowen, Dr Ian Campbell, Ms Tracey Cole, Dr Alexander Dyker, Mrs Gillian Ells, Professor Carol Haigh, Dr Tim Kinnaird and Dr Mohit Sharma

Any other Business

4. None

Appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy [ID840]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr Tim Benepal, Dr Martin Forster and Dr Jesme Fox to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Merck Sharp & Dohme to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Andrew Black, Dr Matthew Bradley, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Professor Paula Ghaneh, Dr Susan Griffin, Professor John Henderson, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Paul Miller and Mrs Gail Coaster all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy
9. The Chair asked all other invited guests to declare their relevant interests.

- 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy
10. The Chair introduced the lead team, Professor Oluwafemi Oyebode, Mr Malcom Oswald and Dr Susan Griffin who gave presentations on the clinical effectiveness and cost effectiveness of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy
 - 14.1. The committee decision was based on consensus.
15. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of necitumumab for untreated advanced or metastatic, squamous non-small-cell lung cancer [ID835]

Part 1 – Open session

16. The Chair welcomed company representatives from Lilly to the meeting.
17. The Chair asked all Committee members to declare any relevant interests
 - 17.1. 7.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Andrew Black, Dr Matthew Bradley, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Professor Paula Ghaneh, Dr Susan Griffin, Professor John Henderson, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, , Dr Paul Miller and Mrs Gail Coaster all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal

non-specific family interest for any of the technologies to be considered as part of the appraisal of necitumumab for untreated advanced or metastatic, squamous non-small-cell lung cancer .

18. The Chair asked all NICE Staff to declare any relevant interests.
 - 18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of necitumumab for untreated advanced or metastatic, squamous non-small-cell lung cancer .
19. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
20. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
21. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

22. The Committee continued to discuss the clinical and cost effectiveness of necitumumab for untreated advanced or metastatic, squamous non-small-cell lung cancer
 - 22.1. The committee decision was based on consensus.
23. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

24. Wednesday 27 July 2016, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.